Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2018

Open Access 01-12-2018 | Research article

A pilot study to profile salivary angiogenic factors to detect head and neck cancers

Authors: L. van der Merwe, Y. Wan, H. J. Cheong, C. Perry, C. Punyadeera

Published in: BMC Cancer | Issue 1/2018

Login to get access

Abstract

Background

Early diagnosis of head and neck squamous cell carcinoma (HNSCCs) is an appealing way to increase survival rates in these patients as well as to improve quality of life post-surgery. Angiogenesis is a hallmark of tumor initiation and progression. We have investigated a panel of angiogenic factors in saliva samples collected from HNSCC patients and controls using the Bio-Plex ProTM assays.

Methods

We have identified a panel of five angiogenic proteins (sEGFR, HGF, sHER2, sIL-6Ra and PECAM-1) to be elevated in the saliva samples collected from HNSCC patients (n = 58) compared to a control cohort (n = 8 smokers and n = 30 non-smokers).

Results

High positive correlations were observed between the following sets of salivary proteins; sEGFR:sHER2, sEGFR:HGF, sEGFR:sIL-6Rα, sHER2:HGF and sHER2:sIL6Ra. A moderate positive correlation was seen between FGF-basic and sEGFR.

Conclusion

We have shown that angiogenic factor levels in saliva can be used as a potential diagnostic biomarker panel in HNSCC.
Appendix
Available only for authorised users
Literature
1.
2.
Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjöstedt E, Asplund A, et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics. 2005;4(12):1920–32.CrossRefPubMed
3.
Balan JJ, Rao RS, Premalatha BR, Patil S. Analysis of tumor marker CA 125 in saliva of normal and oral squamous cell carcinoma patients: a comparative study. J Contemp Dent Pract. 2012;13(5):671–5.CrossRefPubMed
4.
Boysen M, Lövdal O, Winther F, Tausjö J. The value of follow-up in patients treated for squamous cell carcinoma of the head and neck. Eur J Cancer. 1992;28(2):426–30.CrossRefPubMed
5.
Gorugantula LM, Rees T, Plemons J, Chen H-S, Cheng Y-SL. Salivary basic fibroblast growth Factorin patients with oral squamous cell carcinoma or oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114(2):215–22.CrossRefPubMedPubMedCentral
6.
Leemans CR, Braakhuis BJM, Brakenhoff RH. The molecular biology of head and neck cancer. Nature. 2011;11(1):9–22.
7.
Rennemo E, Zätterström U, Boysen M. The increased risk for development of a second cancer after initial treatment of a first h, neck cancer is well known. In this prospectively-collected cohort of pffatodstTmopwstdfdP, a lower mean a: impact of second primary tumors on survival in head and neck Cancer: an analysis of 2,063 cases. Laryngoscope. 2008;118(8):1350–6.CrossRefPubMed
8.
Ovchinnikov DA, Cooper MA, Pandit P, Coman WB, Cooper-White JJ, Keith P, Wolvetang EJ, Slowey PD, Punyadeera C. Tumor-suppressor gene promoter Hypermethylation in saliva of head and neck Cancer patients. Transl Oncol. 2012;5(5):321–6.CrossRefPubMedPubMedCentral
9.
10.
Price KAR, Cohen EE. Current treatment options for metastatic head and neck cancer. Curr Treat Options in Oncol. 2012;13(1):35–46.CrossRef
11.
Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C, et al. Human papillomavirus and survival of patients with oropharyngeal Cancer. N Engl J Med. 2010;363(1):24–35.CrossRefPubMedPubMedCentral
12.
Lechner M, Fenton T, West J, Wilson G, Feber A, Henderson S, Thirlwell C, Dibra HK, Jay A, Butcher L, et al. Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma. Genome Med. 2013;5(2):15.CrossRefPubMedPubMedCentral
13.
Dayyani F, Etzel CJ, Liu M, Ho C-H, Lippman SM, Tsao AS. Research meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2010;2:1–15.CrossRef
14.
Bridges EM, Harris AL. The angiogenic process as a therapeutic target in cancer. Biochem Pharmacol. 2011;81(10):1183–91.CrossRefPubMed
15.
Li D, Chiu H, Gupta V, Chan DW. Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer. Clin Chim Acta. 2012;413(19–20):1506–11.CrossRefPubMedPubMedCentral
16.
Streckfus CF, Storthz KA, Bigler L, Dubinsky WP. A comparison of the proteomic expression in pooled saliva specimens from individuals diagnosed with ductal carcinoma of the breast with and without lymph node involvement. J Oncol. 2009;2009:11.CrossRef
17.
Punyadeera C, Dimeski G, Kostner K, Beyerlein P, Cooper-White J. One-step homogeneous C-reactive protein assay for saliva. J Immunol Methods. 2011;373(1–2):19–25.CrossRefPubMed
18.
Foo JY, Wan Y, Kostner K, Arivalagan A, Atherton J, Cooper-White J, Dimeski G, Punyadeera C. NT-ProBNP levels in saliva and its clinical relevance to heart failure. PLoS One. 2012;7(10):e48452.CrossRefPubMedPubMedCentral
19.
Rao PV, Reddy AP, Lu X, Dasari S, Krishnaprasad A, Biggs E, Roberts CT, Nagalla SR. Proteomic identification of salivary biomarkers of type-2 diabetes. J Proteome Res. 2009;8(1):239–45.CrossRefPubMed
20.
Salazar C, Nagadia R, Pandit P, Cooper-White J, Banerjee N, Dimitrova N, Coman WB, Punyadeera C. A novel saliva-based microRNA biomarker panel to detect head and neck cancers. Cell Oncol (Dordrecht). 2014;37(5):331–8.CrossRef
21.
Pfaffe T, Cooper-White J, Beyerlein P, Kostner K, Punyadeera C. Diagnostic potential of saliva: current state and future applications. Clin Chem. 2011;57(5):675–87.CrossRefPubMed
22.
Yoshizawa JM, Schafer CA, Schafer JJ, Farrell JJ, Paster BJ, Wong DT. Salivary biomarkers: toward future clinical and diagnostic utilities. Clin Microbiol Rev. 2013;26(4):781–91.CrossRefPubMedPubMedCentral
23.
Chai RC, Lim Y, Frazer IH, Wan Y, Perry C, Jones L, Lambie D, Punyadeera C. A pilot study to compare the detection of HPV-16 biomarkers in salivary oral rinses with tumour p16(INK4a) expression in head and neck squamous cell carcinoma patients. BMC Cancer. 2016;16(1):178.CrossRefPubMedPubMedCentral
24.
25.
Mohamed R, Campbell J-L, Cooper-White J, Dimeski G, Punyadeera C. The impact of saliva collection and processing methods on CRP, IgE, and myoglobin immunoassays. Clin Transl Med. 2012;1:19.CrossRefPubMedPubMedCentral
26.
Ovchinnikov DA, Wan Y, Coman WB, Pandit P, Cooper-White JJ, Herman JG, Punyadeera C. DNA methylation at the novel CpG sites in the promoter of MED15/PCQAP gene as a biomarker for head and neck cancers. Biomark Insights. 2014;9:53–60.CrossRefPubMedPubMedCentral
27.
Topkas E, Keith P, Dimeski G, Cooper-White J, Punyadeera C. Evaluation of saliva collection devices for the analysis of proteins. Clin Chim Acta. 2012;413(13–14):1066–70.CrossRefPubMed
28.
Christiansson L, Mustjoki S, Simonsson B, Olsson-Strömberg U, Loskog ASI, Mangsbo SM. The use of multiplex platforms for absolute and relative protein quantification of clinical material. EuPA Open Proteomics. 2014;3:37–47.CrossRef
29.
Friendly M. Corrgrams: exploratory displays for correlation matrices. Am Stat. 2002;56:316–24.CrossRef
30.
31.
Kulasinghe A, Perry C, Jovanovic L, Nelson C, Punyadeera C. Circulating tumour cells in metastatic head and neck cancers. Int J Cancer. 2015;136(11):2515–23.CrossRefPubMed
32.
Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Phys Cell Phys. 2002;282(5):C947–70.CrossRef
33.
Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005;16(2):159–78.CrossRefPubMed
34.
Hasina R, Whipple M, Martin L, Kuo WP, Ohno-Machado L, Lingen MW. Angiogenic heterogeneity in head and neck squamous cell carcinoma: biologic and therapeutic implications. Lab Invest. 2008;88(4):342–53.CrossRefPubMedPubMedCentral
35.
36.
Thomas GR, Nadiminti H, Regalado J. Molecular predictors of clinical outcome in patients with head and neck squamous cell carcinoma. Int J Exp Pathol. 2005;86(6):347–63.CrossRefPubMedPubMedCentral
37.
Pollock NI, Grandis JR. HER2 as a therapeutic target in head and neck squamous cell carcinoma. Clin Cancer Res. 2015;21(3):526–33.CrossRefPubMed
38.
Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012;8(9):1237–47.CrossRefPubMedPubMedCentral
39.
40.
Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J. 2001;15(1):43–58.CrossRefPubMed
41.
Trikha M, Corringham R, Klein B, Rossi J-F. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res. 2003;9(13):4653.PubMedPubMedCentral
42.
Peters M, Jacobs S, Ehlers M, Vollmer P, Müllberg J, Wolf E, Brem G, Meyer zum Büschenfelde KH, Rose-John S. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med. 1996;183(4):1399–406.CrossRefPubMed
43.
Horiuchi S, Koyanagi Y, Zhou Y, Miyamoto H, Tanaka Y, Waki M, Matsumoto A, Yamamoto M, Yamamoto N. Soluble interleukin-6 receptors released from T cell or granulocyte/macrophage cell lines and human peripheral blood mononuclear cells are generated through an alternative splicing mechanism. Eur J Immunol. 1994;24(8):1945–8.CrossRefPubMed
44.
Mullberg J, Oberthur W, Lottspeich F, Mehl E, Dittrich E, Graeve L, Heinrich PC, Rose-John S. The soluble human IL-6 receptor. Mutational characterization of the proteolytic cleavage site. J Immunol. 1994;152(10):4958.PubMed
45.
Müllberg J, Schooltink H, Stoyan T, Günther M, Graeve L, Buse G, Mackiewicz A, Heinrich PC, Rose-John S. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol. 1993;23(2):473–80.CrossRefPubMed
46.
Matsumoto S, Hara T, Mitsuyama K, Yamamoto M, Tsuruta O, Sata M, Scheller J, Rose-John S, Kado S, Takada T. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol. 2010;184(3):1543–51.CrossRefPubMed
47.
Kanazawa T, Nishino H, Hasegawa M, Ohta Y, Iino Y, Ichimura K, Noda Y. Interleukin-6 directly influences proliferation and invasion potential of head and neck cancer cells. Eur Arch Otorhinolaryngol. 2007;264(7):815–21.CrossRefPubMed
Metadata
Title
A pilot study to profile salivary angiogenic factors to detect head and neck cancers
Authors
L. van der Merwe
Y. Wan
H. J. Cheong
C. Perry
C. Punyadeera
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2018
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-018-4656-3

Other articles of this Issue 1/2018

BMC Cancer 1/2018 Go to the issue

Research article

Risk factors for erlotinib-induced hepatotoxicity: a retrospective follow-up study

Research article

Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma

Research article

Prognostic effect of factors involved in revised Tokuhashi score system for patients with spinal metastases: a systematic review and Meta-analysis

Research article

The oncogenic effects of HES1 on salivary adenoid cystic carcinoma cell growth and metastasis

Research article

Sepsis increases perioperative metastases in a murine model

Research article

An elevated expression of serum exosomal microRNA-191, − 21, −451a of pancreatic neoplasm is considered to be efficient diagnostic marker
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits